Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials. Issue 2 (June 2016)

• Record Type: Journal Article
• Authors: Farahnik, Benjamin; Beroukhim, Kourosh; Abrouk, Michael; Nakamura, Mio; Zhu, Tian; Singh, Rasnik; Lee, Kristina; Bhutani, Tina; Koo, John
• Is Part Of: Dermatology and therapy. Volume 6:Issue 2(2016)
• Page Start: 111
• Page End: 124
• Publication Date: 2016-06
• Subjects: AMAGINE -- Anti-interleukin-17 -- Biologics -- Brodalumab -- Interleukin 17 -- Phase III -- Psoriasis; Dermatologic agents -- Periodicals; Skin -- Diseases -- Treatment -- Periodicals; Dermatology -- Periodicals; Skin Diseases -- Periodicals; Dermatologic Agents -- Periodicals; Dermatologic Surgical Procedures -- Periodicals; 616.506
• DOI: 10.1007/s13555-016-0121-x
• Languages: English
• ISSNs: 2193-8210

Abstract

Abstract Introduction Interleukin (IL)-17 inhibitors are the most recent class of monoclonal antibodies approved by the FDA for psoriasis treatment. Preclinical and phase II studies of brodalumab, a high-affinity IL-17 receptor monoclonal antibody, have been encouraging. Methods We conducted a literature search using the PubMed database in order to assess the efficacy and safety profile of brodalumab. The search included the following key words: "psoriasis" and "IL-17" or "brodalumab." We also reviewed citations within articles to identify relevant sources. Results At week 12, the proportion of patients attaining a 75% improvement from the baseline Psoriasis Area and Severity Index (PASI 75) was similar among the three phase III trials (AMAGINE-1, 83%; AMAGINE-2, 86%; AMAGINE-3, 85%). Brodalumab remained efficacious through 52 weeks of treatment. It maintained a satisfactory safety profile; the most frequently reported adverse events consisted of nasopharyngitis, headache, upper respiratory tract infection, and arthralgia. Conclusion Use of brodalumab revealed prompt clinical improvement and a favorable short-term safety profile in phase III trials, although further extension studies are needed to assess long-term safety. Based on the results, brodalumab appears to be a potent therapeutic option for patients with moderate-to-severe plaque-type psoriasis.